drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous CD19-directed CAR T-cell therapy with 4-1BB costimulation/CD3ζ signaling used to target and eliminate CD19+ malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19‑directed chimeric antigen receptor with 4‑1BB costimulation and CD3ζ signaling. Binding to CD19 on B cells activates the CAR T cells, driving proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD19+ malignant B cells, leading to depletion of CD19+ cells.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT05621096